Autonomix Medical Inc Stock Price, News & Analysis

Autonomix Medical (NASDAQ: AMIX) announced a private placement priced at the market under Nasdaq rules to a single institutional investor expected to close on or about November 19, 2025. The investor will purchase 4,501,666 shares of common stock (or pre-funded warrants) plus unregistered Series C warrants to buy up to 9,003,332 additional shares.

The combined effective offering price per share (with accompanying warrant) is $1.1107. Series C warrants carry an exercise price of $0.8607, are exercisable immediately, and expire 5.5 years after issuance. Gross proceeds are estimated at approximately $5.0 million before placement agent fees and expenses. Maxim Group is sole placement agent. The company will file a resale registration statement for the securities.

Autonomix Medical (NASDAQ: AMIX) announced a post-hoc subgroup analysis of its first-in-human PoC 1 study reporting sustained, clinically meaningful quality-of-life gains after targeted transvascular nerve ablation for severe pancreatic cancer pain.

Key numeric findings: symptom scores improved 14.53 points at 4–6 weeks (n=9) and 26.07 points at 3 months (n=6); functionality rose 8.15 and 25.56 points; global QOL improved 8.33 and 18.06 points. Stage 4/metastatic subgroup exceeded EORTC ≥10-point meaningful-change thresholds at multiple timepoints.

The company said results will inform its multicenter U.S. clinical trial planned to start in 2026.

Autonomix Medical (NASDAQ: AMIX) will be featured in two podium presentations at the Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Conference in San Francisco on October 25-28, 2025.

The presentations on Monday, October 27, highlight positive initial results from the first-in-human proof-of-concept clinical study evaluating the safety and effectiveness of transvascular energy to ablate targeted nerves to mitigate pain in patients with pancreatic cancer. Presenter: Robert S. Schwartz, MD, FACC. Session times: 7:30 AM PDT at Innovation Theater, Hall E (“Illuminating the Nervous System with Transvascular Precision-Guided Technology”), and 9:00 AM PDT at Station 5, Halls B-C (“Pain Mitigation in Pancreatic Adenocarcinoma: An Analysis of Denervation via Transvascular RF Energy-Based Ablation”).

Autonomix Medical (NASDAQ: AMIX) will present at the 2025 Maxim Growth Summit in New York on October 22-23, 2025. The company, focused on precision nerve-targeted medical devices, said management will be available for in-person one-on-one meetings with qualified, registered investors during the conference.

The presentation provides an investor-access opportunity to discuss the company’s nerve-sensing and ablation platform and recent developments directly with management. Registration and the full summit agenda are available from the event organizer.

Autonomix (NASDAQ: AMIX) announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,369,852 on October 9, 2025 for "Controlled and Precise Treatment of Cardiac Tissues."

The '852 patent covers systems, devices, and methods that sense autonomic/cardiac signals, map targets, and deliver therapy with closed-loop feedback for precision neuromodulation, denervation, and ablation of cardiac tissues. The filing is described as adding to a global IP portfolio of over 120 issued and pending patent applications and is positioned to address indications including arrhythmias, refractory angina, heart failure, hypertension, and plaque/inflammation modulation.

Autonomix Medical (NASDAQ: AMIX), a medical device company focused on precision nerve-targeted treatments, has released its latest CEO Corner segment featuring CEO Brad Hauser. The segment discusses two key updates: the company's recent longer-term post hoc analysis from its first-in-human proof-of-concept study (PoC 1) and progress towards U.S. clinical trials scheduled to begin in 2026.

Autonomix Medical (NASDAQ: AMIX) has initiated a crucial Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System, targeting pancreatic cancer pain treatment. The study, conducted at CBSET research institute, represents a significant step toward FDA regulatory approvals.

The company remains on track to submit its Investigational Device Exemption (IDE) and, pending approval, begin U.S. clinical trials in 2026 to support a De Novo FDA application. CEO Brad Hauser highlighted this as a critical milestone in their regulatory pathway.

Autonomix's first-in-class technology platform shows potential applications across multiple therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and pulmonary and gastrointestinal disorders.

Autonomix Medical (NASDAQ: AMIX) announced that its technology and findings from the first phase of its first-in-human proof-of-concept study will be presented at the 2025 CIRSE Annual Congress in Barcelona, Spain. The presentation, scheduled for September 15, 2025, will focus on pain mitigation in pancreatic adenocarcinoma using neurolysis via transvascular RF ablation.

The presentation will be part of SPHAIRE, CIRSE's interactive area dedicated to artificial intelligence in interventional radiology. Marco Bedoya, VP of Research and Development at Autonomix, will deliver the presentation during the "AI in IR: Machine Learning, SOP and Collaborative Development" session.

Autonomix Medical (NASDAQ: AMIX), a medical device company specializing in nervous system disease diagnosis and treatment, has released a Virtual Investor "What This Means" segment. In this presentation, Chief Medical Officer Dr. Robert Schwartz discusses the company's recent post hoc analysis of their proof-of-concept human clinical trial (PoC 1).

The analysis revealed significant outcomes including sustained pain reduction, improved quality of life, and 100% zero opioid use among trial participants. The company's focus remains on advancing innovative technologies in neurological disease management.